JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Erythema induratum of Bazin.

Erythema induratum of Bazin is a rare entity, the cause and treatment of which are topics of continuing controversy. This report documents the cases of two patients with ulcerating leg nodules. One patient had concurrent active pulmonary tuberculosis, and the other had a history of previous treatment for pulmonary tuberculosis. The treatment regimen for these patients is outlined. First described by Bazin, the rare entity of erythema induratum was thought to be of tuberculous origin or a tuberculid reaction. Opinion has varied, and some authors have classified this condition as a vasculitis involving subcutaneous vessels. Because of the rarity of this disorder and the controversy surrounding its cause and pathogenesis, we share our experience with two patients whose clinical and pathologic findings were consistent with the diagnostic criteria for erythema induratum and in whom there was a recent or remote history of tuberculosis.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app